Evidence map›Paper›PMID 26798561›Full record

ArticleJournal of AIDS & clinical research2015

Development of IgG Mediated Antibody Dependent Cell-mediated Cytotoxicity (ADCC) in the Serum and Genital Mucosa of HIV Seroconverters.

Mariam Aziz, Fareeha Mahmood, Mariana Mata, Helen G Durkin, Chenglong Liu, Ruth M Greenblatt, Marek Nowicki, Elizabeth T Golub, Kathryn Anastos, Audrey L French and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of AIDS & clinical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Recent Insights into the HIV/AIDS Pandemic.Microbial cell (Graz, Austria) · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Mariam AzizCORE Center, Cook County Health and Hospitals System, Chicago, IL 60612, USA; Division of Infectious Diseases, Rush University Medical Center, Chicago, IL, 60612, USA.
Fareeha MahmoodDepartment of Immunology/Microbiology Rush University Medical Center, Chicago, IL, 60612, USA.
Mariana MataDepartment of Immunology/Microbiology Rush University Medical Center, Chicago, IL, 60612, USA.
Helen G DurkinSUNY Downstate Medical Center, Brooklyn, NY, 11203, USA.
Chenglong LiuGeorgetown University, Washington, DC, 20057, USA.
Ruth M GreenblattUniversity of California, San Francisco, CA, 94110 USA.
Marek NowickiUniversity of Southern California Norris Hospital, Los Angeles, CA, 90033 USA.
Elizabeth T GolubJohns Hopkins University, Baltimore, MD 21218, USA.
Kathryn AnastosMontefiore Medical Center, Bronx, NY, 10467 USA.
Audrey L FrenchCORE Center, Cook County Health and Hospitals System, Chicago, IL 60612, USA; Division of Infectious Diseases, Rush University Medical Center, Chicago, IL, 60612, USA.
Linda L BaumDepartment of Immunology/Microbiology Rush University Medical Center, Chicago, IL, 60612, USA.
Cook County Health and Hospitals System · US

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Women's Interagency HIV Study (WIHS-V)U01AI035004 · NIAID · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI ANASTOS, KATHRYN M., SHARMA, ANJALI · 1993 to 2018
$65.7M
WOMEN'S INTERAGENCY HIV STUDY ORGANIZATION, MANAGEMENT AND COMMUNICATIONSU01AI034989 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AOUIZERAT, BRADLEY E, GREENBLATT, RUTH MARTHA · 1993 to 2018
$65.6M
Women's Interagency HIV Study (WIHS) IIIU01AI031834 · NIAID · SUNY DOWNSTATE MEDICAL CENTER · PI GUSTAFSON, DEBORAH R., MINKOFF, HOWARD · 1998 to 2018
$53.5M
WOMEN'S INTERAGENCY HIV STUDY (WIHS) ORGANIZATION AND MANAGEMENTU01AI034994 · NIAID · GEORGETOWN UNIVERSITY · PI KASSAYE, SEBLE G · 1993 to 2018
$52.0M
Women's Interagency HIV Study (WIHS) IV, Chicago ConsortiumU01AI034993 · NIAID · HEKTOEN INSTITUTE FOR MEDICAL RESEARCH · PI COHEN, MARDGE H, FRENCH, AUDREY · 1994 to 2018
$51.0M
WOMENS INTERAGENCY HIV STUDY (WIHS)U01HD032632 · NICHD · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MILAM, JOEL E · 1994 to 2012
$42.0M
WIHS DATA MANAGEMENT AND ANALYSIS CENTER(WDMAC)U01AI042590 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GANGE, STEPHEN J, GOLUB, ELIZABETH T · 1998 to 2018
$38.4M
Tissue Culture and Virology Laboratory CoreP01AI082971 · NIAID · RUSH UNIVERSITY MEDICAL CENTER · PI LANDAY, ALAN L · 2009 to 2013
$11.2M
DevelopmentalP30AI082151 · NIAID · RUSH UNIVERSITY MEDICAL CENTER · PI LANDAY, ALAN L · 2009 to 2014
$4.6M
NCRR NIH HHS UL1 RR024131NIAID NIH HHS P01 AI082971NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI082151NIAID NIH HHS U01 AI031834NIAID NIH HHS U01 AI034989NIAID NIH HHS U01 AI034993NIAID NIH HHS U01 AI034994NIAID NIH HHS U01 AI035004NIAID NIH HHS U01 AI042590NICHD NIH HHS U01 HD032632
6 · The paper itself

Abstract

backgroundWe measured antibody-dependent cell mediated cytotoxicity (ADCC) activity in serum and genital fluids of heterosexually exposed women during HIV seroconversion.

methodsPlasma and cervico-vaginal lavage (CVL) fluid from 11 seroconverters (SC) were analyzed biannually from one year pre- to 6 year post-seroconversion using a

resultsNo SC had significant HIV specific CVL ADCC activity before seroconversion or until 1.5 yr after seroconversion. One individual had a %Specific Release (SR) of 25.4 at 2 years, 26.7 at 3 years and 21.0 at 4 years after seroconversion in CVL. Another sample had 4.7% SR at 2 years, 5.3 at 3 years, 10.9 at 4 years, and 8.4 at 5 years after seroconversion in CVL. A third had no activity until 17% SR 5 years after seroconversion in CVL. A fourth showed activity of 36.5% SR at 6.5 years after seroconversion. Seven women had no ADCC activity in their CVL. Paired serum samples showed HIV specific ADCC activity prior to the appearance of CVL ADCC activity.

conclusionsHIV specific ADCC activity in CVL rose 2 years after seroconversion; ADCC was present in the serum prior to this time. These data suggest that genital tract ADCC activity is not present until well after acute infection.

Indexed as

Antibody dependent cellular cytotoxicityHIVSeroconvertersWomen

Identifiers

PMID26798561
PMCPMC4718584
OpenAlexW2223260123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.